Werewolf Therapeutics, Inc.

NASDAQ:HOWL

2.34 (USD) • At close September 13, 2024
Bedrijfsnaam Werewolf Therapeutics, Inc.
Symbool HOWL
Munteenheid USD
Prijs 2.34
Beurswaarde 102,263,148
Dividendpercentage 0%
52-weken bereik 1.574 - 8.194
Industrie Biotechnology
Sector Healthcare
CEO Dr. Daniel J. Hicklin Ph.D.
Website https://werewolftx.com

An error occurred while fetching data.

Over Werewolf Therapeutics, Inc.

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates

Vergelijkbare Aandelen

Jasper Therapeutics, Inc. logo

Jasper Therapeutics, Inc.

JSPR

22.75 USD

Annexon, Inc. logo

Annexon, Inc.

ANNX

7.2 USD

UroGen Pharma Ltd. logo

UroGen Pharma Ltd.

URGN

13.12 USD

CVRx, Inc. logo

CVRx, Inc.

CVRX

7.85 USD

Checkpoint Therapeutics, Inc. logo

Checkpoint Therapeutics, Inc.

CKPT

2.3 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)